Federal Appeals Court Upholds Finding that Affymetrix, Navigenics Did Not Infringe MIT Patent | GenomeWeb

NEW YORK (GenomeWeb News) – The US Court of Appeals for the Federal Circuit has upheld a lower court's ruling that Affymetrix and Life Technologies' Navigenics business did not infringe a patent held by E8 Pharmaceuticals and the Massachusetts Institute of Technology.

The court issued its ruling last week saying it was based "solely on our agreement with the district court's construction of the phrase 'randomly primed PCR-derived RCG.' We do not reach any other issues raised on appeal."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.